2010 conference - toward a treatment standard for pathological gambling (grant)
TRANSCRIPT
4 6 8 10
2 4
6 8
10
12
Visit
PG
-YB
OC
S U
rges
Placebo 20mg 40mg
p=.027
Days
84 70 56 42 28 14 0
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1 0.0
Naltrexone / Asp40 Allele (A/G, G/G)
Naltrexone Asn40 Allele (A/A) Placebo / Asp40 Allele (A/G, G/G) Placebo / Asn40 Allele (A/Al)
Days
84 70 56 42 28 14 0
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1 0.0
Naltrexone / Asp40 Allele (A/G, G/G)
Naltrexone Asn40 Allele (A/A) Placebo / Asp40 Allele (A/G, G/G) Placebo / Asn40 Allele (A/Al)
Days
84 70 56 42 28 14 0
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1 0.0
Naltrexone / Asp40 Allele (A/G, G/G)
Naltrexone Asn40 Allele (A/A) Placebo / Asp40 Allele (A/G, G/G) Placebo / Asn40 Allele (A/Al)
Prop
ortio
n N
onre
laps
ed
Analysis of Maximum Likelihood Estimates (N=282)
Variable Parameter Estimate
Standard Error
Chi-Square
Pr>ChiSq Hazard Ratio
FH-AUD 0.55 0.24 7.53 0.006 1.74
Baseline urges were significantly associated with response to higher doses of opiate antagonists (i.e. nalmefene 50mg or 100mg or naltrexone 100mg or 150mg) (parameter estimate = 1.77; SE= 0.84; Wald χ2 =4.41; p= .036; HR= 5.86; HR 95% CI=1.12-30.6
56% reduction in urges; 57% reduction in total gambling symptoms
N-Acetyl Cysteine: 12-Week Open-Label
Visit 1 Visit 6 p-value
PG-YBOCS total score 21.8 8.9 <.001
Responder, n (%) n/a 18 (62.1)
<.001
Dollars lost per week 743 309 <.001
Hours gambled per week 10.4 4.0 <.001
PG B v E PG B v C PG E v C
T P t p t p
IDED total errors 2.20 0.037 2.09 0.041 1.06 0.294
Lexapro Treatment of Anxious Gamblers
Hollander et al, 2002
* *
*
* p<.05
